End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.3 CNY | +0.45% | -4.73% | +58.33% |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+58.33% | 409.01Cr | - | ||
+40.73% | 74TCr | C+ | ||
+31.86% | 60TCr | B | ||
-6.30% | 35TCr | C+ | ||
+15.15% | 32TCr | B- | ||
+4.05% | 28TCr | C+ | ||
+15.40% | 24TCr | B+ | ||
+9.46% | 21TCr | B- | ||
-5.44% | 21TCr | A+ | ||
+6.17% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301301 Stock
- Ratings Yili Chuanning Biotechnology Co.,Ltd.